Your browser doesn't support javascript.
loading
Apremilast retention rate in clinical practice: observations from an Italian multi-center study.
Ariani, Alarico; Parisi, Simone; Del Medico, Patrizia; Farina, Antonella; Visalli, Elisa; Molica Colella, Aldo Biagio; Lumetti, Federica; Caccavale, Rosalba; Scolieri, Palma; Andracco, Romina; Girelli, Francesco; Bravi, Elena; Colina, Matteo; Volpe, Alessandro; Ianniello, Aurora; Franchina, Veronica; Platè, Ilaria; Di Donato, Eleonora; Amato, Giorgio; Salvarani, Carlo; Lucchini, Gianluca; De Lucia, Francesco; Molica Colella, Francesco; Santilli, Daniele; Ferrero, Giulio; Marchetta, Antonio; Arrigoni, Eugenio; Mozzani, Flavio; Foti, Rosario; Sandri, Gilda; Bruzzese, Vincenzo; Paroli, Marino; Fusaro, Enrico; Becciolini, Andrea.
Afiliação
  • Ariani A; Internal Medicine and Rheumatology Unit, University Hospital of Parma, Parma, Italy. dott.alaricoariani@libero.it.
  • Parisi S; Rheumatology Department, Azienda Ospedaliera Universitaria Città Della Salute E Della Scienza Di Torino, Turin, Italy.
  • Del Medico P; Rheumatology Outpatient Clinic, Internal Medicine Unit, Civitanova Marche Hospital, Civitanova Marche, Italy.
  • Farina A; Internal Medicine Unit, Rheumatology Outpatient Clinic, Ospedale "A. Murri", Fermo, Italy.
  • Visalli E; Rheumatology Unit, Policlinico San Marco University Hospital of Catania, Catania, Italy.
  • Molica Colella AB; Rheumatology Unit, Azienda Ospedaliera Papardo, Messina, Italy.
  • Lumetti F; Rheumatology Unit, Azienda USL of Modena and University Hospital, "Policlinico Di Modena", Modena, Italy.
  • Caccavale R; Department of Biotechnology and Medical-Surgical Sciences, Sapienza University of Rome, Polo Pontino, Latina, Italy.
  • Scolieri P; Unit of Internal Medicine and Rheumatology, "Nuovo Regina Margherita / S. Spirito" Hospital, ASL Roma 1, Rome, Italy.
  • Andracco R; Internal Medicine Unit, Imperia Hospital, Imperia, Italy.
  • Girelli F; Rheumatology Unit, Ospedale GB Morgagni - L Pierantoni, Forlì, Italy.
  • Bravi E; Internal Medicine and Rheumatology Unit, Ospedale G. Da Saliceto, Piacenza, Italy.
  • Colina M; Rheumatology Service, Section of Internal Medicine, Department of Medicine and Oncology Unit, Ospedale Santa Maria della Scaletta, Imola, Italy.
  • Volpe A; Unit of Rheumatology, IRCCS Sacro Cuore Don Calabria Hospital, Negrar, Verona, Italy.
  • Ianniello A; Rheumatology Outpatient Unit, ASL Novara, Novara, Italy.
  • Franchina V; UOC Oncologia Medica Azienda Ospedaliera Papardo, Messina, Italy.
  • Platè I; Internal Medicine and Rheumatology Unit, Ospedale G. Da Saliceto, Piacenza, Italy.
  • Di Donato E; Internal Medicine and Rheumatology Unit, University Hospital of Parma, Parma, Italy.
  • Amato G; Rheumatology Unit, Policlinico San Marco University Hospital of Catania, Catania, Italy.
  • Salvarani C; Rheumatology Unit, University of Modena and Reggio Emilia, Azienda Ospedaliero-Universitaria, Policlinico Di Modena, Modena, Italy.
  • Lucchini G; Internal Medicine and Rheumatology Unit, University Hospital of Parma, Parma, Italy.
  • De Lucia F; Rheumatology Unit, Policlinico San Marco University Hospital of Catania, Catania, Italy.
  • Molica Colella F; Internal Medicine Unit, University of Milano-Bicocca, Milan, Italy.
  • Santilli D; Internal Medicine and Rheumatology Unit, University Hospital of Parma, Parma, Italy.
  • Ferrero G; Unit of Diagnostic and Interventional Radiology, Santa Corona Hospital, Pietra Ligure, Italy.
  • Marchetta A; Unit of Rheumatology, IRCCS Sacro Cuore Don Calabria Hospital, Negrar, Verona, Italy.
  • Arrigoni E; Internal Medicine and Rheumatology Unit, Ospedale G. Da Saliceto, Piacenza, Italy.
  • Mozzani F; Internal Medicine and Rheumatology Unit, University Hospital of Parma, Parma, Italy.
  • Foti R; Rheumatology Unit, Policlinico San Marco University Hospital of Catania, Catania, Italy.
  • Sandri G; Rheumatology Unit, University of Modena and Reggio Emilia, Azienda Ospedaliero-Universitaria, Policlinico Di Modena, Modena, Italy.
  • Bruzzese V; Unit of Internal Medicine and Rheumatology, "Nuovo Regina Margherita / S. Spirito" Hospital, ASL Roma 1, Rome, Italy.
  • Paroli M; Department of Biotechnology and Medical-Surgical Sciences, Sapienza University of Rome, Polo Pontino, Latina, Italy.
  • Fusaro E; Rheumatology Department, Azienda Ospedaliera Universitaria Città Della Salute E Della Scienza Di Torino, Turin, Italy.
  • Becciolini A; Internal Medicine and Rheumatology Unit, University Hospital of Parma, Parma, Italy.
Clin Rheumatol ; 41(10): 3219-3225, 2022 Oct.
Article em En | MEDLINE | ID: mdl-35796847
OBJECTIVE: There are few real-world setting studies focused on apremilast effectiveness (i.e., retention rate) in psoriatic arthritis (PsA). The main aim of this retrospective observational study is the assessment of apremilast 3-year retention rate in real-world PsA patients. Moreover, the secondary objective is to report the reasons of apremilast discontinuation and the factors related to treatment persistence. METHODS: In fifteen Italian rheumatological referral centers, all PsA consecutive patients who received apremilast were enrolled. Anamnestic data, treatment history, and PsA disease activity (DAPSA) at baseline were recorded. The Kaplan-Meier curve and the Cox analysis computed the apremilast retention rate and treatment persistence-related risk factors. A p-value < 0.05 was considered statistically significant. RESULTS: The 356 enrolled patients (median age 60 [interquartile range IQR 52-67] yrs; male prevalence 42.7%) median observation period was 17 [IQR 7-34] months (7218 patients-months). The apremilast retention rate at 12, 24, and 36 months was, respectively, 85.6%, 73.6%, and 61.8%. The main discontinuation reasons were secondary inefficacy (34% of interruptions), gastro-intestinal intolerance (24%), and primary inefficacy (19%). Age and oligo-articular phenotype were related to treatment persistence (respectively hazard ratio 0.98 IQR 0.96-0.99; p = 0.048 and 0.54 IQR 0.31-0.95; p = 0.03). CONCLUSION: Almost three-fifths of PsA patients receiving apremilast were still in treatment after 3 years. This study confirmed its effectiveness and safety profile. Apremilast appears as a good treatment choice in all oligo-articular PsA patients and in those ones burdened by relevant comorbidities. Key Points • Apremilast retention rates in this real-life cohort and trials are comparable. • The oligo-articular phenotype is associated with long-lasting treatment (i.e., 3 years). • No different or more prevalent adverse events were observed.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Artrite Psoriásica / Antirreumáticos Tipo de estudo: Observational_studies / Risk_factors_studies Limite: Humans / Male Idioma: En Revista: Clin Rheumatol Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Itália

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Artrite Psoriásica / Antirreumáticos Tipo de estudo: Observational_studies / Risk_factors_studies Limite: Humans / Male Idioma: En Revista: Clin Rheumatol Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Itália